中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2015年
17期
881-885
,共5页
金静思%贺巾钊(综述)%周黎明(审校)
金靜思%賀巾釗(綜述)%週黎明(審校)
금정사%하건쇠(종술)%주려명(심교)
非小细胞肺癌%分子靶向治疗药物%个体化治疗
非小細胞肺癌%分子靶嚮治療藥物%箇體化治療
비소세포폐암%분자파향치료약물%개체화치료
non-small cell lung cancer%molecular-targeted therapeutic drugs%individualized treatment
目前肺癌以高发病率、高死亡率居我国恶性肿瘤病死率的首位,严重威胁着人类的健康,其中非小细胞肺癌(non-small cell lung cancer,NSCLC)约占肺癌的80%~90%。遗憾的是大多数患者就诊时已为晚期,错失了外科手术的机会,故内科治疗成为NSCLC晚期患者的主要治疗方法。近些年来分子靶向治疗药物取得了巨大的进展,为NSCLC晚期患者提供了新的治疗手段。本文将就NSCLC的分子靶向药物治疗作一介绍,希望能对临床上NSCLC晚期患者的个体化治疗有所裨益。
目前肺癌以高髮病率、高死亡率居我國噁性腫瘤病死率的首位,嚴重威脅著人類的健康,其中非小細胞肺癌(non-small cell lung cancer,NSCLC)約佔肺癌的80%~90%。遺憾的是大多數患者就診時已為晚期,錯失瞭外科手術的機會,故內科治療成為NSCLC晚期患者的主要治療方法。近些年來分子靶嚮治療藥物取得瞭巨大的進展,為NSCLC晚期患者提供瞭新的治療手段。本文將就NSCLC的分子靶嚮藥物治療作一介紹,希望能對臨床上NSCLC晚期患者的箇體化治療有所裨益。
목전폐암이고발병솔、고사망솔거아국악성종류병사솔적수위,엄중위협착인류적건강,기중비소세포폐암(non-small cell lung cancer,NSCLC)약점폐암적80%~90%。유감적시대다수환자취진시이위만기,착실료외과수술적궤회,고내과치료성위NSCLC만기환자적주요치료방법。근사년래분자파향치료약물취득료거대적진전,위NSCLC만기환자제공료신적치료수단。본문장취NSCLC적분자파향약물치료작일개소,희망능대림상상NSCLC만기환자적개체화치료유소비익。
Lung cancer is ranked the first among all malignant neoplastic diseases because of its high morbidity and mortality rate. Thus, lung cancer seriously threatens human health. More than 80%of lung cancer cases are non-small cell lung cancer (NSCLC). Unfortunately, the majority of NSCLC patients are already at the terminal stage of the disease when they seek medical attention. Such patients miss the optimal opportunity of surgery;thus, medical treatment becomes the main choice for them. Recently, molecular-target-ed therapy has made tremendous progress in clinical practice and provides a new potential treatment for patients at the terminal stage. In this review, the authors introduced some molecular-targeted therapeutic drugs to provide benefits for the individualized treatment of patients.